US Rheumatologists Show Continued Uptake of Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis, Though Safety Concerns and Lack of Experience in the Market Withhold Full Potential - P&T Community
US Rheumatologists Show Continued Uptake of Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis, Though Safety Concerns and Lack of Experience in the Market Withhold Full Potential P&T Community
EXTON, Pa., March 25, 2019 /PRNewswire/ -- Overall brand share among biologic/JAK-treated patients in the US rheumatoid arthritis (RA) market has remained ...
Comments
Post a Comment